Advice
in the absence of a submission from the holder of the marketing authorisation:
dupilumab (Dupixent®) is not recommended for use within NHSScotland.
Indication under review: treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice286KB (PDF)
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2896
- Indication:
Treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Skin
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 19 January 2026